United Therapeutics (FRA:UTH) 3-Year EBITDA Growth Rate

: 20.40% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

United Therapeutics's EBITDA per Share for the three months ended in Dec. 2023 was €5.95.

During the past 12 months, United Therapeutics's average EBITDA Per Share Growth Rate was 30.80% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 20.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of United Therapeutics was 128.00% per year. The lowest was -10.10% per year. And the median was 21.55% per year.

Competitive Comparison

For the Biotechnology subindustry, United Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

United Therapeutics 3-Year EBITDA Growth Rate Distribution

For the Biotechnology industry and Healthcare sector, United Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where United Therapeutics's 3-Year EBITDA Growth Rate falls into.

United Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

United Therapeutics (FRA:UTH) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

United Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of United Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

United Therapeutics (FRA:UTH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (FRA:UTH) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

UTHR:USA UTH:Germany

Address

1040 Spring Street, Silver Spring, MD, USA, 20910

Website

https://www.unither.com

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

United Therapeutics (FRA:UTH) Headlines

No Headlines